INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

Akebia Therapeutics, Inc.

AKBACIK 0001517022

EDGAR filingsOpen in network
Price$0.40
1 year-81.1%
Disclosed transactions11
Buys / sells0 / 5
Max Insider Score23
Connections with evidence7

AKBA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
FR
Frieson RonDirector
AKBAAkebia Therapeutics, Inc.
Grant or award
A—
53.6K sh
Jun 17, 2026Jun 22, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Connected organizationevidence
    AKEBIA THERAPEUTICS INC POLITICAL ACTION COMMITTEEFEC Form 1 connected organization: AKEBIA THERAPEUTICS INC. (exact legal-name match) · Nov 4, 2026
  • ← Lobbied forevidence
    BGR GOVERNMENT AFFAIRSLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    THE PETRIZZO GROUP, INC.LDA Q1 2026 first quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Insider ofevidence
traded Jun 17, 2026
+5d
SEC FORM 4

Evidence

23
FR
Frieson RonDirector
AKBAAkebia Therapeutics, Inc.
Grant or award
A—
35.7K sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$35K
25.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

10
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$19K
13.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

17
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$50K
36.1K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
16.8K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$38K
27.5K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

17
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Grant or award
A—
190.0K sh
Jan 30, 2026Feb 3, 2026
traded Jan 30, 2026
+4dSEC FORM 4

Evidence

9
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Grant or award
A—
119.0K sh
Jan 30, 2026Feb 3, 2026
traded Jan 30, 2026
+4dSEC FORM 4

Evidence

17
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Grant or award
A—
79.0K sh
Jan 30, 2026Feb 3, 2026
traded Jan 30, 2026
+4dSEC FORM 4

Evidence

9
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Grant or award
A—
270.0K sh
Jan 30, 2026Feb 3, 2026
traded Jan 30, 2026
+4dSEC FORM 4

Evidence

Frieson Ron
Director · Jun 22, 2026
  • ← Insider ofevidence
    Rucci Carolyn M.SVP, Chief Legal Officer · Feb 3, 2026
  • ← Insider ofevidence
    Malabre Richard CSVP, Chief Accounting Officer · Feb 3, 2026

    • Lobbying

    $1.10M reported · de-duplicated
    2026 Q3 $260K in-house2026 Q2 $360K in-house2026 Q1 $480K in-house
    • In-house report$260K2026 Q3 · posted Nov 3, 2026 · Health issues, Medicare/Medicaid
    • THE PETRIZZO GROUP, INC.$45K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • In-house report$360K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • THE PETRIZZO GROUP, INC.$60K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • BGR GOVERNMENT AFFAIRS$60K2026 Q2 · posted Aug 26, 2026 · Health issues
    • In-house report$480K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • BGR GOVERNMENT AFFAIRS$60K2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members
    • Jason SmithR$7,000AKEBIA THERAPEUTICS INC POLITICAL ACTION COMMITTEE
    • Carol D. MillerR$3,500AKEBIA THERAPEUTICS INC POLITICAL ACTION COMMITTEE
    • Michael A. RulliR$1,000AKEBIA THERAPEUTICS INC POLITICAL ACTION COMMITTEE
    • Adrian SmithR$1,000AKEBIA THERAPEUTICS INC POLITICAL ACTION COMMITTEE